ACT-10041239 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Demyelinating Diseases. According to GlobalData, Phase I drugs for Demyelinating Diseases have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACT-10041239’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ACT-10041239 overview

ACT-10041239 is under development for the treatment of multiple sclerosis and other demyelinating diseases. The therapeutic candidate is formulated as hard gelatin capsule and is administered by oral route.
It was also under development for the treatment of cancer and unspecified immunological disorders.

Idorsia Pharmaceutical overview

Idorsia Pharmaceutical (Idorsia), a subsidiary of Idorsia Ltd, is a biopharmaceutical company that discovers, develops, and commercializes small molecules. The company’s portfolio products include daridorexant, aprocitentan, lucerastat, sinbaglustat, ACT-777991, ACT-1014-6470, IDOR-1117-2520 and others. Its products treat therapeutic areas such as central nervous system (CNS), cardiovascular, immunological disorders and orphan diseases. Idorsia collaborates with Janssen Biotech to develop and commercialize aprocitentan drug candidates. The company operates through offices in the Netherlands and Switzerland. Idorsia is headquartered in Allschwil, Basel-Landschaft, Switzerland.

For a complete picture of ACT-10041239’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.